Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...
Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene (NGNE – Research Report) and keeping the price target at ...
The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side ...
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant ...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter ...
GlobalData on MSN8d
Neurogene’s stock sinks after adverse event with Rett syndrome gene therapyNeurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback